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Abstract
Background: Nowadays, the majority of patients with myocardial infarction with ST-segment eleva-
tion (STEMI) are treated with primary percutaneous coronary interventions (PCI). In recent years, 
there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. 
However, reports on further mortality reduction among PCI-treated STEMI patients remain incon-
clusive. The aim of this study was to compare changes in management and mortality in PCI-treated 
STEMI patients between 2005 and 2011 in a real-life setting. 
Methods: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary 
Syndromes (PL-ACS) admitted to Polish hospitals between 2005 and 2011 were analyzed. First, tem-
poral trends of in-hospital management in men and women were presented. In the next step, patients 
from 2005 and 2011 were nearest neighbor matched on their propensity scores to compare in-hospital, 
30-day and 1-year mortality rates and in-hospital management strategies and complications. 
Results: Some significant changes were noted in hospital management including shortening of median 
times from admission to PCI, increased use of drug-eluting stents, potent antiplatelet agents but also less 
frequent use of statin, beta-blockers and angiotensin converting enzyme inhibitors and angiotensin II 
receptor blockers. There was a strong tendency toward preforming additional PCI of non-infarct related 
arteries, especially in women. After propensity score adjustment there were significant changes in in-
hospital but not in 30-day or 1-year mortality rates between 2005 and 2011. The results were similar 
in men and women.
Conclusions: There were apparent changes in management and significant in-hospital mortality  
reductions in PCI-treated STEMI patients between 2005 and 2011. However, it did not result in  
30-day or 1-year survival benefit at a population level. There may be  room for improvement in the use 
of guideline-recommended pharmacotherapy. (Cardiol J 2019; 26, 5: 459–468)
Key words: ST-segment elevation myocardial infarction, percutaneous coronary  
intervention, temporal trends, treatment strategy, in-hospital mortality, 1-year mortality, 
sex-differences
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Introduction
Most of recent studies have confirmed 
a significant reduction in mortality rates among pa-
tients with myocardial infarction with ST-segment 
elevation (STEMI) during the last 10–20 years 
[1–3]. The increased use of percutaneous coronary 
interventions (PCI) has unquestionably been key 
improvement in STEMI treatment. Nevertheless, 
there are other important changes evolving in PCI 
techniques and new evidence-based concomitant 
pharmacotherapy. Recent advances in angioplasty 
devices, including manual aspiration catheters and 
drug-eluting stents (DES), potent antiplatelet and 
anticoagulant agents, have significantly enhanced 
outcomes for STEMI patients [4], not to mention 
shorter door-to-balloon (D2B) times, growing 
experience of operators performing PCI and ef-
forts put into implementation of evidence-based 
treatments into real-life clinical practice. However, 
the scope and reasons for the observed decline in 
mortality remain inconclusive, especially among 
PCI-treated patients and in sex-specific analyses. 
A large study from Northern Italy presented 
a weak temporal trend in mortality reduction from 
2000 to 2010 in men only, despite increases in the 
use of an invasive approach in both sexes [5]. In 
contrast, an American study including patients with 
STEMI who underwent primary PCI from 2003 to 
2008 reported a tendency toward decreased in-
hospital mortality only among women but even that 
was not statistically significant [6]. Some newer 
studies including mostly patients treated with PCI 
showed that there was no further improvement 
regarding in-hospital [7], 30-day [8] or 1-year 
mortality despite changes in patient characteristics 
and concomitant treatment [9]. On the other hand, 
French data demonstrated a decrease in 30-day 
mortality rates also among patients treated with 
PCI from 1995 to 2010 [10]. Similarly, British in-
vestigators found that 6-month survival improved 
significantly from 2003 to 2010 for STEMI patients 
who received reperfusion therapy [11].
Clinical profiles of STEMI patients have been 
changing over time and it has already been dem-
onstrated in the Polish population [12]. Female 
STEMI patients differ significantly from males [13] 
and may undergo independent temporal changes in 
terms of clinical characteristics and modes of treat-
ment [12, 14], which warrants separate analyses 
of both sexes. It was reported that women are less 
likely to undergo proper reperfusion treatment 
[1, 3, 15] and to receive early drug therapies even 
after adjustment for baseline characteristics [1]. 
Recently published registry data have also shown 
that, despite advances in care, women continue to 
experience higher mortality rates compared with 
men in STEMI [16] or after PCI for coronary artery 
disease [17]. 
The aims of this study are to compare changes 
and analyze temporal trends in hospital manage-
ment of men and women with STEMI treated 
with PCI from 2005 to 2011 and determine if it 
resulted in better in-hospital, 30-day and 1-year 
survival rates.
Methods
The Polish Registry of Acute Coronary Syn-
dromes (PL-ACS) is an ongoing, nationwide, multi-
center, prospective, observational study of patients 
hospitalized with acute coronary syndromes (ACS). 
The registry is a joint initiative of the Silesian 
Center for Heart Diseases and the Polish Ministry 
of Health. Patients admitted with suspected ACS 
were screened for their eligibility to enter the 
registry, but they were not enrolled until ACS was 
confirmed. During the study period, 449 hospitals 
participated in the registry, 132 of them with PCI 
facilities and 20 with onsite cardiac surgery. The 
registry covered around 70% of all hospitals where 
STEMI patients were treated in Poland including 
primary, secondary and tertiary-level hospitals as 
well as academic and university centers. 
In the current study all patients enrolled in the 
PL-ACS Registry hospitalized between 2005 and 
2011 with the diagnosis of STEMI were evaluated 
(111,148). Of them, 79,522 (71.5%) were treated 
with PCI and were included in further analyses 
(25,155 women and 54,367 men). STEMI was 
defined as the presence of ST-segment elevation 
of ≥ 2 mm in the contiguous chest leads and/or 
ST-segment elevation of ≥ 1 mm in two or more 
standard leads or a new left bundle branch block, 
together with positive cardiac necrosis markers 
(cardiac troponin or creatine kinase-MB). For the 
patients who presented more than once during the 
study period only the first hospitalization was ana-
lyzed. All-cause mortality data were obtained from 
the official mortality records of the National Health 
Fund. The vital statuses at discharge, 30-day and 
1-year were available for all patients included. 
The study adhered to the Declaration of Helsinki 
and its revision from 2008 and was approved by 
the Bioethics Committee at the Swietokrzyska 
Chamber of Physicians.
Temporal trends for in-hospital PCI-related 
treatment strategies were presented (D2B times, 
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PCI type, Thrombolysis in Myocardial Infarction 
[TIMI] flow 3 after PCI, additional PCI of any 
non-infarct-related artery (IRA) during index hos-
pitalization). Continuous variables were presented 
as means ± standard deviation or median ± inter-
quartile range, depending on the normality of the 
distribution. Categorical variables were presented 
as counts and percentages. The significance of the 
time trends was tested with Jonckheere-Terpstra 
test for continuous variables and Cochran-Armit-
age test for categorical variables. 
To adjust data from 2005 and 2011 available 
baseline characteristics of PCI-treated patients 
(Table 1) were incorporated into a regression 
model to estimate a propensity score (PS) of each 
individual. In the next step, the patients from 2011 
were nearest neighbor matched on their PS to 
patients from 2005. A total of 15,886 individuals 
were successfully matched within a pre-defined 
PS distance. Women and men were analyzed sepa-
rately. Standardized differences were calculated 
for assessing balance in baseline characteristics 
between subjects from 2005 and 2011 (Table 1). 
The overlap and the region of common support be-
tween the groups were checked by  visual analysis. 
In-hospital treatment strategies including pharma-
cotherapy, in-hospital complications (myocardial 
reinfarction, ischemic stroke and major bleeding) 
as well as in-hospital, 30-day and 1-year mortality 
rates were compared between patients from 2005 
and 2011. Significance of differences between the 
study groups was assessed by the Student t-test 
or Mann-Whitney U test for continuous variables 
and c2 test for categorical variables. A two-sided 
p value ≤ 0.05 was considered significant.
The calculations and statistical analyses were 
performed with STATISTICA 10 (StatSoft Inc., 
Tulsa, OK, USA), MedCalc (MedCalc Software, Bel-
gium) and SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Results
The fraction of patients treated with PCI was 
increasing annually from 53.3% in 2005 to 93.8% 
in 2011. A majority of patients included in the 
analysis were treated with primary PCI. Small and 
declining percentages of all PCI-treated patients 
had PCI after thrombolysis or PCI followed by 
emergent coronary artery bypass grafting during 
index hospitalization. Detailed unadjusted trends 
are presented in Tables 2 and 3. TIMI flow after 
PCI was reported in 99% of patients.
When comparing crude data men were more 
often treated with PCI and more often had TIMI 3 
flow after PCI than women — both in 2005 and 
2011 (p < 0.001). Bare metal stents (BMS) were 
more often implanted in men in 2005 (p = 0.001) 
but not in 2011 (p = 0.53) whereas DES were more 
often implanted in men in 2011 (p = 0.003) but not 
in 2005 (p = 0.07). Women more frequently had 
at least one additional PCI of non-IRA in 2011 
(p < 0.001) but not in 2005 (p = 0.55). There was 
a strong trend (1.6% average absolute change 
per year) towards increased fractions of women 
undergoing additional PCI of non-IRA whereas 
a corresponding trend in male patients was only 0.3% 
per year. The differences in D2B times were not 
statistically significant between sexes (p = 0.32 in 
2005 and  p = 0.1 in 2011). However, the 1–2 min 
longer D2B times in women were reported rela-
tively constantly throughout the study period.
Following adjustment of 2005 and 2011 popu-
lations with PS matching technique many notable 
differences were observed in treatment strategies in-
cluding in-hospital pharmacotherapy (Tables 4 and 5).
A substantial increase in additional PCI of non-
IRA, particularly in women, was also confirmed in 
PS-matched subgroups; thus, it proved to be likely 
unrelated to temporal changes in initial character-
istics. There was an increase in hospital colpidogrel 
and glycoprotein IIb/IIIa inhibitors usage in both 
sexes. At the same time there was a decrease in 
acetylsalicylic acid (ASA), beta-blockers, statins and 
angiotensin converting enzyme inhibitors (ACEI) or 
angiotensin II receptor blockers (ARBs) usage in 
both sexes. The percentage of patients who received 
ASA at discharge increased in 2011 when compare 
to in-hospital usage and was not significantly differ-
ent from the percentage observed in 2005. At the 
same time some patients who were given in-hospital 
clopidogrel were discharged without this drug. In-
hospital complications were rare; there was a further 
decline in the number of myocardial reinfarctions 
and ischemic strokes (only in women) and non-
statistically significant increase in major bleeding 
was reported during hospitalization. In-hospital mor-
tality rates of STEMI patients decreased between 
2005 and 2011 in both sexes. However, there was 
no significant change in 30-day or 1-year mortality 
rates in neither men nor women (Tables 4 and 5).
Discussion
The main finding of this study is that, despite 
numerous advances in hospital management and 
in-hospital mortality reduction, no significant decrease 
in 30-day or 1-year mortality was observed. In fact, the 
first 30 days was critical in terms of STEMI patients 
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Table 1. Clinical characteristics on admission after propensity score matching.
Women (n = 5253) Men (n = 10633)
2005 
N = 2615
2011 
N = 2638
S. Diff. 2005  
N = 5328
2011  
N = 5305
S. Diff.
Age 67.1 ± 11.1 67.5 ± 12.2 0.05 60.5 ± 11.2 60.8 ± 11.2 0.04
Hypertension 68.9% 66.5% –0.05 58.7% 59.9% 0.02
Diabetes 28.6% 25.7% –0.07 16.7% 17.5% 0.02
Hypercholesterolemia 43.7% 42.9% –0.02 40.4% 40.8% 0.01
Current smoking 31.8% 30.7% –0.02 60.7% 61.7% 0.02
Obesity 24.9% 22.8% –0.05 13.9% 15.1% 0.03
Prior MI 7.8% 7.9% 0.00 9.7% 9.3% –0.01
Prior PCI 1.4% 1.4% 0.00 2.2% 2% –0.01
Prior CABG 1% 1% 0.00 1.8% 1.7% –0.01
Systolic BP on admission [mmHg]:
< 100 8.1% 9.3% 0.04 7.4% 7% –0.02
100–160 73.6% 72.7% –0.02 75.8% 75.3% –0.01
> 160 18.3% 18% –0.01 16.8% 17.7% 0.02
ECG on admission (rhythm):
Sinus rhythm 92.2% 91.2% –0.04 93.6% 93.9% 0.01
Atrial fibrillation 5.8% 5.8% 0.00 4% 4% 0.00
Pacing 0.2% 0.3% 0.02 0.2% 0.2% 0.00
Other 1.8% 1.9% 0.01 2.2% 1.9% –0.02
HR > 100/min 7.7% 7.8% 0.00 6.6% 6.5% 0.00
ECG on admission (intraventricular conduction):
Normal 89.1% 88.9% –0.01 88.6% 88.8% 0.01
LBBB 1.8% 1.9% 0.01 1.5% 1.4% –0.01
RBBB 2.6% 2.6% 0.00 3.5% 3.2% –0.02
Other 6.5% 6.6% 0.00 6.5% 6.5% 0.00
Infarct location:
Anterior 39.8% 41.1% 0.03 40.2% 40% 0.00
Inferior 50.3% 50.2% 0.00 51.5% 51.3% 0.00
Other 9.9% 8.8% –0.04 8.3% 8.7% 0.01
Time from symptom-onset to admission [h]:
0–2 21.5% 21.7% 0.00 25.8% 25.5% –0.01
2–12 63.5% 61.6% –0.04 58.8% 60.1% 0.03
> 12 15% 16.7% 0.05 15.3% 14.4% –0.03
Prehospital cardiac arrest 2% 2.3% 0.02 3.3% 2.8% –0.03
Killip class on admission:
IV 6.2% 5.8% –0.02 4.7% 4.7% 0.00
III 2.1% 1.9% –0.01 1.7% 1.5% –0.02
II 10.7% 10.1% –0.02 9.4% 9.9% 0.02
I 81% 82.2% 0.03 84.2% 83.8% –0.01
LVEF [%]:
> 50% 49% 47.1% –0.04 48.7% 49.1% 0.01
30–50% 46% 47.8% 0.04 46.6% 46% –0.01
< 30% 5% 5.2% 0.01 4.7% 4.8% 0.00
BP — blood pressure; CABG — coronary artery bypass grafting; ECG — electrocardiogram; HR — heart rate; LBBB — left bundle branch 
block; LVEF — left ventricular ejection fraction; MI — myocardial infarction; PCI — percutaneous coronary intervention; RBBB — right bundle 
branch block; S. Diff. — standardized difference
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prognosis as patients who survive the first month after 
STEMI treated with primary PCI have only a < 1.5% 
annual risk of successive cardiac death [18]. There 
have been major improvements in the delivery of care 
for STEMI patients including the increased use of PCI 
and adjunctive therapies, but at the same time some 
unexpected tendencies in guideline-recommended 
pharmacotherapy were noted. 
Significant reductions were observed of-in 
hospital D2B delays which is consistent with ob-
servations of other authors [19, 20]. Only patients 
who had PCI performed within 12 h from symptom 
onset were analyzed, thus the present results 
have shorter D2B times than most other studies. 
The medians of D2B times shortened slightly but 
significantly between 2005 and 2011 — compromis-
ing the right direction of changes in management. 
Women continue to have longer D2B times but the 
average difference between sexes was only around 
1–2 min. It was not statistically significant but 
remained relatively constant throughout the study 
period. A study of STEMI patients in Australia 
analyzing D2B time components have confirmed 
longer delays in both diagnosis and instituting PCI 
therapy in women [21]. A potential factor that may 
contribute to the delay may be related to anatomic 
factors including smaller diameter of coronary 
vessels in women [22] and potential technical dif-
ficulties in performing the PCI. Possibly for the 
same reason optimal — TIMI 3 flow after PCI was 
more often achieved in men during the study period 
and no significant trend toward reduction of this 
particular sex discrepancy was noted. 
Drug eluting stent compared with BMS are 
not associated with morality reduction but they 
improve clinical outcomes by reducing the risk of 
reintervention [23]. DES is currently preferred 
over BMS in STEMI patients without contrain-
Table 4. Changes in management and 30-day mortality of percutaneous coronary intervention (PCI)-
-treated women with ST-segment elevation myocardial infarction from 2005 and 2011 matched on  
propensity scores.
2005 2011 P
Door to balloon time [min] 47 (30–75) 43 (30–65) < 0.001
Additional PCI of non-IRA 8.6% 18.4% < 0.001
PCI type: 9.6% 7.1% < 0.001
Balloon angioplasty
Bare metal stent 89.3% 76.3% < 0.001
Drug eluting stent 1.1% 16.6% < 0.001
TIMI 3 flow after PCI 88.8% 90.6% 0.032
In-hospital pharmacotherapy: 96.0% 89.2% < 0.001
ASA
Clopidogrel 77.4% 98.9% < 0.001
GP IIb/IIIa inhibitors 24.6% 31.1% < 0.001
Beta-blockers 79.3% 70.1% < 0.001
Statins 84.3% 75.4% < 0.001
ACEIs or ARBs 77.1% 64.6% < 0.001
In-hospital complications: 3.1% 0.2% < 0.001
Myocardial reinfarction
Ischemic stroke 0.8% 0.3% 0.005
Major bleeding 1.3% 1.7% 0.23
Pharmacotherapy at discharge:
ASA 95.9% 95.9% 0.93
Clopidogrel 41.4% 92.5% < 0.001
In-hospital mortality 7.5% 5.7% 0.011
30-day mortality 9.1% 8.9% 0.84
1-year mortality 14.5% 13.9% 0.5
ACEIs — angiotensin converting enzyme inhibitors; ASA — acetylsalicylic acid; ARBs — angiotensin II receptor blockers; GP IIb/IIa — glyco-
protein IIb/IIIa; non-IRA — non-infarct related artery; TIMI — Thrombolysis in Myocardial Infarction
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dications to prolonged dual antiplatelet therapy 
[24]. It was observed that women are less likely to 
receive DES. The potential gender-related differ-
ences in stent type selection might be related to 
a physician’s notion of an increased risk of bleeding 
in women on prolonged dual antiplatelet therapy, 
their statistically greater age or other non-specific 
sex-related disparities. However, the frequency of 
use of DES has been significantly increasing for 
both sexes presumably due to better availability 
and an increasingly established role of DES as 
a standard mode of treatment in ACS. 
In patients with STEMI undergoing infarct-
artery PCI benefits of PCI in non-infarct coronary 
arteries with major stenoses is a subject of debate. 
European Society of Cardiology (ESC) Guidelines 
present during the study period did not clearly refer 
to treating non-infarct related vessels, apart from 
suggesting  treatment of the infarct-related lesion 
by PCI and perform coronary artery bypass grafting 
later under more stable conditions. Later, in 2012 
ESC Guidelines stated that primary PCI should 
be limited to the culprit vessel with the excep-
tion of cardiogenic shock and persistent ischemia 
after PCI of the supposed culprit lesion [24]. 
However, recent CULPRIT-SHOCK trial showed 
that additional intervention on non infarct-related 
lesions in cardiogenic shock was associated with 
higher 30-day risk of unfavorable outcomes [25]. 
The 2013 American College of Cardiology Foun-
dation/American Heart Association (ACCF/AHA) 
Guidelines designated a Class III recommendation 
for multivessel primary PCI in hemodynamically 
stable patients with STEMI; it has recently been 
modified to a Class IIb in the 2015 Update [26]. 
Recently published results of PRAMI [27], CvL-
PRIT [28] and DANAMI-3 PRIMULTI [29] trials 
showed that complete revascularization during the 
Table 5. Changes in management and 30-day mortality of percutaneous coronary intervention (PCI)-
-treated men with ST-segment elevation myocardial infarction from 2005 and 2011 matched on  
propensity scores.
2005 2011 P
Door to balloon time [min] 46 (30–72) 41 (30–62) < 0.001
Additional PCI of non-IRA 8.6% 9.8% 0.032
PCI type:
Balloon angioplasty 7.8% 5.1% < 0.001
Bare metal stent 91.6% 75.8% < 0.001
Drug eluting stent 0.6% 19% < 0.001
TIMI 3 flow after PCI 91.1% 92.5% 0.013
In-hospital pharmacotherapy:
ASA 96.3% 90.6% < 0.001
Clopidogrel 78.3% 98.8% < 0.001
GP IIb/IIIa inhibitors 28.1% 35.6% < 0.001
Beta-blockers 81.3% 75.9% < 0.001
Statins 87.0% 81.3% < 0.001
ACEIs or ARBs 78.5% 69.8% < 0.001
In-hospital complications:
Myocardial reinfarction 2.9% 0.3% < 0.001
Ischemic stroke 0.2% 0.2% 0.69
Major bleeding 0.6% 0.8% 0.079
Pharmacotherapy at discharge:
ASA 96.8% 96.5% 0.46
Clopidogrel 43% 93,1% < 0.001
In-hospital mortality 4.1% 3.3% 0.034
30-day mortality 5.4% 5.5% 0.86
1-year mortality 9.5% 9.7% 0.73
ACEIs — angiotensin converting enzyme inhibitors; ASA — acetylsalicylic acid; ARBs — angiotensin II receptor blockers; GP IIb/IIa — glyco-
protein IIb/IIIa; non-IRA — non-infarct related artery; TIMI — Thrombolysis in Myocardial Infarction
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index admission in patients with STEMI and mul-
tivessel disease may be of benefit. Those results 
have already been incorporated into the current 
2017 ESC STEMI Guidelines [30]. An unexpected 
finding is that the percentage of women undergo-
ing additional PCI of at least one non-IRA almost 
doubled during the study period whereas a corre-
sponding trend in male patients was over 5 times 
weaker. Although, in general, women tend to have 
a more diffused disease, it most probably could not 
fully explain such a strong trend. Despite a lack of 
recommendations for routine preventive PCI in 
STEMI patients, it had been performed in women 
surprisingly often and only forthcoming trials were 
to confirm that this is a safe and potentially benefi-
cial approach. It is interesting and warrants further 
studies of other potential underlying causes.
The frequencies of the use of novel antiplatelet 
agents (clopidogrel and glycoprotein IIb/IIIa inhibi-
tors) have increased. This is not surprising with 
regard to the importance of platelet inhibition in 
PCI-treated patients. In contrast, at the same time 
the use of ASA and other evidence based medi-
cine-based medications have decreased. Single 
authors reported similar tendencies in ASA usage 
in secondary prevention and hypothesized that it 
may be attributable to a rise in novel antiplatelet 
agent usage, and physicians being less insistent on 
dual antiplatelet therapy in patients with a minor 
intolerance to ASA [11]. However, in the present 
study the percentages of patients who were rec-
ommended ASA at discharge were comparable 
between 2005 and 2011. On the other hand, some 
patients who received in-hospital clopidogrel were 
discharged without this drug, especially in 2005, 
which might be related to possible economic issues 
and the use of another thienopyridine (ticlopidine) 
instead. There may also have been a small number 
of patients who had STEMI in the mechanism other 
than atherosclerosis and there was a decision not to 
prolong aggressive antiplatelet therapy. Significant 
decreases in the use of beta-adrenolytic agents, 
ACEI or ARBs and statins was unexpected. Early 
ACE inhibition was shown to reduce mortality 
as early as 30 days after STEMI, with most of 
the benefit observed during the first week [31]. 
Statins lower both short and long-term mortality 
in MI patients and is most beneficial when treat-
ment is initiated which was observed early after 
admission to the hospital [32]. On the other hand, 
the administration of early beta-blocker therapy in 
acute MI has failed to prove a net benefit on mortal-
ity [33], despite well-established benefits in longer 
observations. It has gradually been realized that 
the greatest benefit of using beta-blockers and 
ACEI is expected in selected groups of patients 
(i.e. those with heart failure or left ventricular 
dysfunction) and our observations may reflect 
a tendency toward a more discriminating usage 
of those drugs. Nevertheless, there is no data 
to confirm this hypothesis as this observation 
may be related to lower quality of care as well. 
Especially taking into account that 2012 and 
2017 ESC Guidelines presented high IIA Class 
of recommendation for the routine beta-blocker 
and ACEI use in all patients without contraindi-
cations [24, 30]. A significant decrease in statin 
use in the present study is alarming and presents 
an unclear tendency. Optimal medical therapy 
could be as important as reperfusion therapy 
in the PCI era [34]. Some pitfalls in this field 
could explain why no further mortality reduc-
tion was observed despite substantial changes 
in STEMI management. A similar analysis (data 
not published yet) that included all patients, 
regardless of treatment strategy, showed better 
pharmacotherapy standards. This may reflect 
an improper tendency to pay less attention to 
concomitant pharmacotherapy in patients who 
have undergone PCI reperfusion.
In-hospital complication rates considerably 
declined, which undoubtedly helped to achieve 
better in-hospital survival rates. Myocardial re-
infarctions became less frequent in both sexes. 
Ischemic strokes were already rare in 2005 in men 
and their rates significantly decreased in women. 
The rates of major bleeding during hospitalization 
showed an insignificant rise in both sexes. This 
effect was most likely due to an increased use 
of antiplatelet (and possibly also antithrombotic) 
agents. However, taking into account significant 
declines in rates of reinfarctions and ischemic 
strokes, no significant increase in major bleedings 
suggest an acceptable safety profile of new manage-
ment approaches.
There are wide differences in reported mortal-
ity rates of STEMI patients and treatment-related 
statistics across countries [6, 8, 11]. However, in 
this study mostly data in propensity score matched 
cohorts allowed for comparing changes between 
2005 and 2011 were presented but may not reflect 
actual frequencies observed in the whole popula-
tion, so comparisons with other studies are not 
applicable. The focus herein was mainly on the 
survival benefit from ongoing changes in treatment 
among PCI-treated patients and, as mentioned 
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before, data from other studies which have shown 
inconsistent results [6–10]. It was believed that 
each region should be analyzed separately to ex-
plore potential factors contributing to variations in 
outcomes of STEMI patients in the PCI-era.
Limitations of the study
A number of possible limitations of this study 
should be mentioned. First, it is retrospective in 
nature using registry data. Participation in PL-ACS 
Registry is voluntary and participating sites varied 
during the study period so selection bias cannot 
be excluded. Some initial patient characteristics 
were not available (for example data on renal 
failure or anemia) which might have affected PS 
model quality. Also some information on treatment 
strategy (for example data on thrombus aspiration 
or catheterization access — radial vs. femoral) 
and data on post-discharge treatment, including 
pharmacotherapy and the length of dual antiplatelet 
therapy, were not available. Unavailable records 
of post-discharge management (compliance to 
prescribed pharmacotherapy, rehabilitation or the 
rates of cardioverter-defibrillator implantations) 
could also be considered important predictors of 
medium and long-term mortality.
Conclusions
Many changes in PCI techniques and concomi-
tant management in patients with STEMI treated 
with PCI between 2005 and 2011 in Poland and 
a significant reduction of their in-hospital mortality 
rates were noted.  However, no significant reduc-
tion in 30-day or 1-year mortality was observed. 
These results have been analogous in male and 
female populations. The observed trends in treat-
ment strategies have generally presented ongoing 
improvement which followed current guidelines. 
There remains room for further improvement in 
the field of concomitant in-hospital pharmaco-
therapy among PCI-treated patients. Although 
randomized control trials have confirmed efficiency 
of particular interventions, their overall association 
with medium and long-term mortality reduction 
at the population level was not confirmed in this 
study. It could be related to implementation rates 
of new treatments in a real-life setting and should 
not be interpreted as calling into question their 
individual-level of usefulness. 
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